Copper and zinc concentrations in biological material as a survival marker in patients with kidney cancer in Poland
PL451230A1Pending Publication Date: 2026-08-24READ GENE SPOKA AKCYJNA
2 Cites 0 Cited by
Patent Information
- Application Number
- PL2025451230
- Authority / Receiving Office
- PL · PL
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-02-17
- Publication Date
- 2026-08-24
Abstract
The subject of the application is a method for determining the risk of death in patients diagnosed with kidney cancer, characterized in that it includes a quantitative assessment of the concentration of copper in a whole blood sample of the tested person, wherein the concentration of copper in the blood sample within the range of 843 - 928 µg / l indicates a 5-fold reduced risk of death and a 13-fold reduced risk of death due to kidney cancer in relation to patients with a copper concentration in the whole blood sample above 1038 µg / l.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Serum copper concentration as a prognostic marker in patients with prostate cancer in Poland
PL436999A1
Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland
PL437046A1